Morepen Laboratories Ltd

Morepen Laboratories Ltd

Morepen Laboratories Ltd has released its Q1 FY 27 Investor Presentation, highlighting a 34% YoY increase in revenue, 207% YoY increase in EBITDA, and 394% YoY increase in PAT. The company attributes this performance to operational execution and commercial validation of its Morepen 2.0 strategy.

Morepen Laboratories Ltd

Morepen Laboratories Ltd has announced its Q1 FY 27 Financial Results, with the Board of Directors approving the un-audited standalone & consolidated financial results for the quarter ended June 30, 2026. The company has also declared a record date for determining members eligible to receive final dividend for the financial year ended March 31, 2026, subject to approval at the 41st Annual General Meeting. Additionally, the Board has approved the re-appointment of Mr. Sushil Suri as the Chairman & Managing Director for a further period of three years, subject to approval at the 41st AGM.

Morepen Laboratories Ltd

Morepen Laboratories Ltd has announced its Q1 FY 27 financial results, with the Board of Directors considering and approving the un-audited standalone & consolidated financial results for the quarter ended June 30, 2026. The company has also announced a record date for the final dividend for the financial year ended March 31, 2026, and the re-appointment of Mr. Sushil Suri as the Chairman & Managing Director for a further period of three years.

Morepen Laboratories Ltd

Morepen Laboratories Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 04/08/2026 to consider and approve financial results for Q-1 FY27. The trading window will remain closed till 48 hours after the declaration of financial results.

Morepen Laboratories Ltd

Morepen Laboratories Ltd has changed the name of its wholly owned subsidiary company from Morepen Labs - FZCO to Morepen Labs FZE, following the migration of the company's subsidiary from the International Free Zone Authority to the Jebel Ali Free Zone.